Lack of Funding Drives Biotech to Suspend Drug-Resistant Antibiotic Pipeline
Despite the increasing need for antibiotics against drug-resistant bacteria, companies are finding it hard to make a play in the field due to lack of funding. Five-year-old X-Biotix announced it is throwing in the towel on its antibacterial research efforts and changing gears for its corporate strategy.
“This issue is driven by a critical lack of sustained sources of funding to support early-stage research in this field, combined with lack of an appropriate market infrastructure to support the successful commercialization of novel antibiotics,” said Stephen Isaacs, Chairman of X-Biotix.
After a successful Series A in 2018, X-Biotix was in the process of advancing a novel pipeline of first-in-class programs. Two programs directed against LpxA and LpxC, Gram-negative targets, validated a pathway for which there are currently no antibiotics available.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).
